CTKB
CYTEK BIOSCIENCES, INC.NasdaqResearch view
Healthcare · Laboratory Analytical Instruments · Small-cap · SEC EDGAR FY 2025-12-31
Price history
Chart: TradingView’s own feed · page prices: 1D EOD🔒 Click to interact · scroll moves the page
Snapshot
SEC EDGAR · FY 2025-12-31SectorHealthcare
Market Cap$688.9M
Enterprise Value$598.1M
Income$-66.5M
Sales$201.5M
Book/sh$2.63
Cash/sh$0.70
Dividend TTM—
Payout—
Employees—
IPO—
Quick Ratio4.42
Current Ratio5.04
Debt/Eq—
EPS (ttm)$-0.09
EPS this Y-550.0%
EPS past 3/5Y—
Sales past 3/5Y7.1%
EPS Y/Y TTM-550.0%
Sales Y/Y TTM0.5%
Shs Outstand129.98M
ROA-14.4%
ROE-19.5%
ROIC-35.9%
Gross Margin51.8%
Oper. Margin-20.0%
Profit Margin-33.0%
Every figure here is filed with the SEC. Valuation and estimate metrics (P/E, PEG, EV/EBITDA, price targets, forward EPS) are omitted until our market-data feed is licensed for display — we’d rather show fewer numbers than blank ones. Deeper lines (cash flow, balance sheet) below.
Revenue & Earnings — fiscal year
$128.0M
2021
$164.0M
2022
$193.0M
2023
$200.5M
2024
$201.5M
2025
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $128.0M | $164.0M | $193.0M | $200.5M | $201.5M |
| Gross Profit | $79.1M | $101.0M | $109.4M | $111.1M | $104.5M |
| Operating Income | $9.2M | $-1.8M | $-27.8M | $-20.5M | $-40.4M |
| Net Income | $3.0M | $2.5M | $-12.1M | $-6.0M | $-66.5M |
| Diluted EPS | $0.00 | $0.02 | $-0.09 | — | — |
| Operating Cash Flow | $4.6M | $-12.2M | $5.3M | $25.4M | $-4.7M |
| Free Cash Flow | $266,000 | $-22.0M | $633,000 | $21.9M | $-8.8M |
Deep dive
Computed from the SEC EDGAR multi-year statementsOperating leverage — margins
GrossOperatingNet
FY25 cash-flow waterfall
Cash-flow detail unavailable in this filing.
—
COMMUNITY · $CTKB0 theses
POST YOUR TAKE →Related Stocks
Click to exploreSame Industry · Laboratory Analytical Instruments
Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.